Hidradentitis supprativa (HS) trial

Hidradenitis suppurativa is an inflammatory skin disease affecting apocrine bearing areas such as the axillae and groin, characterised by recurrent discharging abscesses and sinuses, inflammatory nodules and scarring.
The Westmead Dermatology Department is currently recruiting patients with HS for a phase 2 study evaluating the efficacy of bimekizumab in patients with moderate to severe hidradenitis suppurativa. Patients will be treated for 12 weeks, and will be randomised 2:1:1 to bimekizumab, adalimumab and placebo, respectively. They will also be followed up for an additional 20 weeks after last dosing.
Eligibility criteria:
1. 18 to 70 years.
2. Active disease at screening, with a diagnosis of HS for at least 1 year
3. Inadequate response to at least 3 months of oral antibiotics for treatment of HS.
Please call or email us should you have any queries on wm.derm.ct@sydney.edu.au or (02) 8890 5686. If you have eligible patients, kindly fax a referral to (02) 8890 9673.
Written by Dr Rose Liu